Personalized and Precision Medicine Journal
Where Innovations Meets Personalized and Precision Medicine

Increased expression of the lnc H19 gene in the plasma of people with breast cancer

Document Type : Original Article

Authors

kazhaleh Mohammadi 1
Sadegh Shojaei Baghini 2
Mohammad Ali Saremi 3

1 Researcher and lecture assistant at the Medical Laboratory Science Department, Knowledge University, Kurdistan Region, Erbil, Iraq

2 Plant Biotechnology, Agriculture Biotechnology Department, National Institute of Genetics Engineering and Biotechnology, Tehran, Iran

3 Personalized Medicine Research Center of AmitisGen, Tehran, Iran

https://doi.org/10.22034/pmj.2020.43454
Abstract
The majority of ncRNAs are known as long non-coding RNAs (lncRNAs) whose length exceeds 200 nucleotides. H19, a lncRNA, is the transcription product of the H19 gene, an oncogene in breast cancer, and is highly expressed in cancer tissues compared with normal tissues. The expression level of H19 is associated with the oncogenesis, proliferation, invasion, metastasis, and drug resistance of breast cancer. H19 expression levels were detected in breast cancer plasma using qRT-Real-Time PCR assay in 50 breast cancer samples and 50 healthy control samples. The results showed that the expression of this gene in both the tissue and the plasma of patients increased compared to that of healthy individuals.

Keywords

lncRNAs
breast cancer
gene expression
plasma
qRT-Real-Time PCR
  1. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, Stadler PF, Hertel J, Hackermuller J, Hofacker IL, et al: RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 316:1484-1488,2007.
  2. Dahariya S, Paddibhatla I, Kumar S, Raghuwanshi S, Pallepati A and Gutti RK: Long non‑coding RNA: Classification, biogenesis and functions in blood cells. Mol Immunol 112: 82-92, 2019.
  3. M.J. Duffy, D. Evoy and E.W. McDermott, CA 15-3: uses and limitation as a biomarker for breast cancer, Clin Chim Acta 411 (2010), 1869-1874.
  4. N. Patani, L.A. Martin and M. Dowsett, Biomarkers for the clinical management of breast cancer: international perspective, Int J Cancer 133 (2013), 1-13.

5.S. van Heesch, M. van Iterson, J. Jacobi, et al., Extensive localization of long noncoding RNAs to the cytosol and monoand polyribosomal complexes, Genome Biol 15 (2014), R6.

  1. Raveh E, Matouk IJ, Gilon M and Hochberg A: The H19 Long non-coding RNA in cancer initiation, progression and metastasis-a proposed unifying theory. Mol Cancer14:184,2015.

7.Yoshimura H, Matsuda Y, Yamamoto M, Kamiya S and Ishiwata T: Expression and role of long non-coding RNA H19 in carcinogenesis. Front Biosci (Landmark Ed) 23: 614-625, 2018.

  1. Bao MH, Szeto V, Yang BB, Zhu SZ, Sun HS and Feng ZP: Long non-coding RNAs in ischemic stroke. Cell Death Dis 9: 281, 2018.
  2. Zeng Y, Li TL, Zhang HB, Deng JL, Zhang R, Sun H, Wan ZR, Liu YZ, Zhu YS and Wang G: Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer. Pharmacogenomics 20: 179-188, 2019.
  3. Ghaedi H, Zare A, Omrani MD, Doustimotlagh AH, Meshkani R, Alipoor S and Alipoor B: Genetic variants in long noncoding RNA H19 and MEG3 confer risk of type 2 diabetes in an Iranian population. Gene 675: 265-271, 2018.
  4. N. Giannoukakis, C. Deal, J. Paquette, et al., Parental genomic imprinting of the human IGF2 gene, Nat Genet 4 (1993), 98101.
  5. T. Dugimont, J.J. Curgy, N. Wernert, et al., The H19 gene is expressed within both epithelial and stromal components of human invasive adenocarcinomas, Biol Cell 85 (1995), 117124.
  6. E. Adriaenssens, S. Lottin, T. Dugimont, et al., Steroid hormones modulate H19 gene expression in both mammary gland and uterus, Oncogene 18 (1999), 4460-4473.
  7. M. Zhu, Q. Chen, X. Liu, et al., lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI, FEBS J 281 (2014), 3766-3775.
  8. M. Zhu, Q. Chen, X. Liu, et al., lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI, FEBS J 281 (2014), 3766-3775.
  9. M. Zhu, Q. Chen, X. Liu, et al., lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI, FEBS J 281 (2014), 3766-3775.
  10. Y.J. Jiang and D.D. Bikle, LncRNA: a new player in 1alpha, 25(OH)(2) vitamin D(3) /VDR protection against skin cancer formation, Exp Dermatol 23 (2014), 147-150.
  11. Z.F. Yang, P. Ngai, D.W. Ho, et al., Identification of local and circulating cancer stem cells in human liver cancer, Hepatology 47 (2008), 919-928.
  12. Zhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li LY, Guan GH, Liu Q, Qian YH and Xie D: The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b. Sci Signal 10: pii: eaak9557,2017
  13. Zhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li LY, Guan GH, Liu Q, Qian YH and Xie D: The lncRNA H19 mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b. Sci Signal 10: pii: eaak9557, 2017.

21. De Martino M, Forzati F, Marfella M, Pellecchia S, Arra C, Terracciano L, Fusco A and Esposito F: HMGA1P7-pseudogene regulates H19 and Igf2 expression by a competitive endogenous RNA mechanism. Sci Rep 6: 37622, 2016.

Personalized and Precision Medicine Journal
Volume 5, Issue 17
Original article
Spring 2020
Pages 12-14

  • Receive Date 26 July 2020

Home

Publication Ethics

Guide for Authors

Submit Manuscript

Contact Us